Levi Garraway, Roche CMO

Roche nabs an FDA OK for Gavre­to, trig­ger­ing a heavy­weight bout with ri­vals at Eli Lil­ly

Four months af­ter Eli Lil­ly’s Retev­mo got the first FDA OK to treat RET-al­tered tu­mors, Roche and Blue­print Med­i­cines are step­ping in­to the ring with re­cent­ly-ap­proved Gavre­to.

The Roche drug was ap­proved on Fri­day to treat non-small cell lung can­cer (NSCLC) pa­tients with RET fu­sions, which are on­ly present in about 1% to 2% of pa­tients, ac­cord­ing to Roche CMO Levi Gar­raway, who called the OK  “an im­por­tant step to­wards our goal of pro­vid­ing an ef­fec­tive treat­ment op­tion for every per­son di­ag­nosed with lung can­cer, no mat­ter how rare or hard-to-treat their type of dis­ease.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.